BioNTech SE - American Depositary Shares (NQ:BNTX)

92.50 +1.04 (+1.14%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

71 72 Next >

Carnival, BioNTech And 3 Stocks To Watch Heading Into Monday ↗

March 27, 2023

With US futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Investor Fear Increases Amid Recent Bank Concerns ↗

March 27, 2023

The CNN Money Fear and Greed index showed some increase in the fear level among U.S. investors. US stocks closed higher on Friday following a volatile trading session. All the major indices recorded...

Via Benzinga

BioNTech Earnings Preview ↗

March 24, 2023

Via Benzinga

4 Analysts Have This to Say About BioNTech ↗

March 23, 2023

Via Benzinga

7 Blue-Chip Stocks Sitting in the Sweet Spot ↗

March 23, 2023

Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move.

Via InvestorPlace

China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine ↗

March 22, 2023

Chinese health authorities approved CSPC Pharmaceuticals Group Ltd's (OTC: CSPCY) messenger RNA (mRNA) COVID-19 vaccine for emergency use authorization.

Via Benzinga

Price Over Earnings Overview: BioNTech ↗

March 20, 2023

Via Benzinga

BioNTech Q4 2022 Earnings Conference Call On March 27, 2023 At 08:00 AM ET ↗

March 16, 2023

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

February 20, 2023

Via Benzinga

Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks ↗

March 21, 2023

The U.S. Food and Drug Administration is reportedly moving toward authorizing a second round of omicron-targeted COVID-19 booster shots for the elderly and other people at high risk.

Via Benzinga

Covid Vaccine Battle Brewing: Moderna's Stephane Bancel Vs. Bernie Sanders ↗

March 21, 2023

Moderna CEO Stephane Bancel will face a Senate Committee over pricing plans.

Via Investor's Business Daily

Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information ↗

March 21, 2023

Via Benzinga

Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose ↗

March 21, 2023

From now on, Moderna Inc (NASDAQ: MRNA) expects to charge $130 per dose for its COVID-19 vaccine as purchases move from the government to the private sector.

Via Benzinga

BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications

March 20, 2023

From BioNTech SE

Via GlobeNewswire

7 Stocks Set to Soar When the Market Recovers ↗

March 16, 2023

Daring contrarians can bid up the danger with these intriguing market ideas.

Via InvestorPlace

FDA Approves Pfizer/BioNTech's Bivalent COVID-19 Vaccine For Youngest Kids ↗

March 15, 2023

Via Benzinga

Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines? ↗

March 14, 2023

Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr.

Via Benzinga

BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023

March 13, 2023

From BioNTech SE

Via GlobeNewswire

Wall Street Thinks These 2 Undervalued Stocks Have Exceptional Growth Potential ↗

March 10, 2023

They're both facing the same fierce headwind, and it won't be going away soon.

Via The Motley Fool

How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising ↗

March 03, 2023

Via Benzinga

European Commission Keeps Mum On Talks Regarding Pfizer COVID-19 Vaccine Contract: Report ↗

March 02, 2023

European Commission President Ursula von der Leyen remains silent on her dealings with Pfizer Inc (NYSE: PFE) regarding the EU's COVID-19 vaccine contract is hurting public trust.

Via Benzinga

BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel

March 01, 2023

From BioNTech SE

Via GlobeNewswire

The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks ↗

February 24, 2023

Startling cancer vaccine results from Moderna may point to the next big thing in biotech.

Via Investor's Business Daily

Pfizer/BioNTech Seek Expanded Approval For Its Updated COVID-19 Shot As Primary Series Vaccination ↗

February 24, 2023

Via Benzinga

Pharma Giant Pfizer Looks Strong for Investors, Despite COVID Sales Drop ↗

February 23, 2023

The company is doubling down on its vaccine success.

Via The Motley Fool

Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees ↗

February 17, 2023

Shares crumbled after Moderna's flu shot outperformed in just one flu strain.

Via Investor's Business Daily

Why Is Moderna (MRNA) Stock Down 5% Today? ↗

February 17, 2023

If Moderna's new formulation works the latest failure will be a short-term hiccup. But MRNA stock also faces legal and PR challenges.

Via InvestorPlace

Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents ↗

February 17, 2023

Via Benzinga

Is Novavax Stock a Buy With the New Normal for COVID? ↗

February 10, 2023

The landscape has shifted dramatically in the COVID-19 vaccine market.

Via The Motley Fool

The 3 Most Undervalued Growth Stocks for Your February Buy List ↗

February 06, 2023

These undervalued growth stocks have the value and projected growth that investors seek when researching their next investment decisions.

Via InvestorPlace

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

71 72 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.